EM2201D "Hypertrophic Cardiomyopathy Update: 2022" (IM GR-012822)

Purpose: To understand the incidence/risks/and treatment of atrial fibrillation

Overview: Non FDA labelled uses of drugs are frequent in HCM, in fact no drug has an FDA approved label specifically for HCM

Target Audience

UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Understand the pathophysiology of hypertrophic cardiomyopathy (HCM).
  • Understand the difference between sarcomeric positive and sarcomeric negative HCM.
  • Understand how patients with HCM develop symptoms of heart failure and to know the indications for septal ablation and myomectomy.
  • Understand the risk of sudden cardiac death in patients with HCM and the indications for implantable defibrillators.
Course summary
Available credit: 
  • 1.00 AMA
Course opens: 
Course expires: 

Photo: Mark Link, M.D.Mark Link, M.D.
Professor of Internal Medicine
Division of Cardiology

Available Credit

  • 1.00 AMA


Please login or create an account to take this course.

Required Hardware/software

Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox and Google Chrome